Carlos D. Malvestutto

发表

Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment

A. Heredia, N. Le, R. Redfield, 2007, AIDS.

The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis

P. Klotman, C. Parikh, S. Coca, 2008, AIDS.

HIV and Dyslipidemia

J. Aberg, C. Malvestutto, Carlos D. Malvestutto, 2020, Contemporary Cardiology.

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV

C. Fichtenbaum, J. Currier, J. Aberg, 2023, eBioMedicine.

Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C

W. Miller, C. Hurt, Jessica Barrett, 2018, Current HIV/AIDS Reports.

Management of dyslipidemia in HIV-infected patients.

J. Aberg, C. Malvestutto, Carlos D. Malvestutto, 2011, Clinical lipidology.

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

Michael T. Lu, G. Bloomfield, C. Fichtenbaum, 2023, The New England journal of medicine.

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

A. Rancourt, C. Fichtenbaum, P. Douglas, 2020, HIV research & clinical practice.

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology

Anqi Li, Yuzhou Chang, Zequn Sun, 2022, Journal of Hematology & Oncology.

TREATMENT WITH SOLUBLE CD24 ATTENUATES COVID-19-ASSOCIATED SYSTEMIC IMMUNOPATHOLOGY

Dongjun Chung, Mohammad Yusuf, C. Bolyard, 2021, medRxiv.

Syringe Service Program Utilization, Barriers, and Preferences for Design in Rural Appalachia: Differences between Men and Women Who Inject Drugs

J. Bridges, H. Cooper, Christopher R. Browning, 2020, Substance use & misuse.

Weight Gain in People with HIV: The role of demographics, antiretroviral therapy, and lifestyle factors on weight.

M. Lustberg, C. Malvestutto, Sheila Okere, 2023, AIDS research and human retroviruses.

Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection

C. Clish, D. Hanna, H. Hodis, 2022, Arteriosclerosis, thrombosis, and vascular biology.

Associations Between HIV Serostatus and Cardiac Structure and Function Evaluated by 2‐Dimensional Echocardiography in the Multicenter AIDS Cohort Study

Katherine C. Wu, M. Budoff, J. Lima, 2021, Journal of the American Heart Association.

Coronary heart disease in people infected with HIV

J. Aberg, C. Malvestutto, Carlos D. Malvestutto, 2010, Cleveland Clinic Journal of Medicine.

Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function

C. Fichtenbaum, P. Sax, D. Haas, 2023, Journal of acquired immune deficiency syndromes.

Management of lipid disorders in patients living with HIV

M. Myerson, J. Aberg, C. Malvestutto, 2015, Journal of clinical pharmacology.

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2021, JAMA network open.

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Karen L. Price, A. Perelson, R. Ribeiro, 2022, Nature Communications.

In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles

M. Lederman, M. Cameron, S. Koletar, 2020, Antimicrobial Agents and Chemotherapy.

Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV

G. Bloomfield, C. Fichtenbaum, P. Douglas, 2022, Journal of acquired immune deficiency syndromes.

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study

Yang Liu, S. Koletar, J. Lake, 2022, The Lancet Infectious Diseases.

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV

C. Fichtenbaum, T. Burdo, T. Mayrhofer, 2024, JAMA cardiology.

Challenges of Statins in HIV Hyperlipidemia

J. Aberg, C. Malvestutto, Carlos D. Malvestutto, 2013 .

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data.

C. Fichtenbaum, J. Aberg, S. Grinspoon, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV

C. Fichtenbaum, T. Burdo, H. Ribaudo, 2024, Journal of acquired immune deficiency syndromes.

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

A. Perelson, M. Hughes, W. Fischer, 2021, medRxiv.

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

C. Fichtenbaum, P. Douglas, J. Currier, 2021, Open forum infectious diseases.